MENLO PARK, Calif. and SINGAPORE, June 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the third and final webinar in its series of Key Opinion Leader (KOL) events on the emerging atopic dermatitis (AD) landscape and eblasakimab (ASLAN004) on Wednesday, June 22, 2022, at 10:00am ET.
ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
/Meta%20by%20creativeneko%20via%20Shutterstock.jpg)
/Tesla%20charging%20station%20black%20background%20by%20Blomst%20via%20Pixabay.jpg)